Aerie Pharmaceuticals Incの営業利益
Aerie Pharmaceuticals Incの営業利益は何ですか。
Aerie Pharmaceuticals Incの営業利益は-12.49%です。
営業利益の定義は何ですか。
営業利益率は、営業利益を純売上高で除したもので、パーセントで表しています。
Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.
NASDAQのセクタHealth Careにおける営業利益の企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似の営業利益
- Reliance Industrial Infrastructureの営業利益は-12.51%です。
- Fresh Express Delivery Coの営業利益は-12.51%です。
- Manfield Chemicalの営業利益は-12.50%です。
- Northeast Electric Developmentの営業利益は-12.50%です。
- BlackBerryの営業利益は-12.50%です。
- Little Green Pharma Ltdの営業利益は-12.49%です。
- Aerie Pharmaceuticals Incの営業利益は-12.49%です。
- Tasty plcの営業利益は-12.48%です。
- Uniphos Enterprisesの営業利益は-12.48%です。
- Perma-Fix Environmental Servicesの営業利益は-12.48%です。
- Misonix Incの営業利益は-12.48%です。
- RIWIの営業利益は-12.46%です。
- Altareit SCAの営業利益は-12.45%です。